Conference on Retroviruses and Opportunistic Infections (CROI 2023), Seattle, Washington, 19-22 February 2023

Poster presentation:

• Trends in mortality in people living with HIV in an international cohort (RESPOND) presented by Erich Tusch on behalf of the RESPOND Study Group. POSTER and PRESENTATION
   
• Chronic liver inflammation and use of contemporary ART among persons living with HIV presented by Ashley Roen on behalf of the RESPOND Study Group. POSTER
   

IWHOD 2023, Athens, Greece, 23-25 March 2023

Oral presentation:

• Association between changes in body mass index and risk of hypertension and dyslipidaemia in people treated with integrase inhibitors and tenofovir alafenamide versus other contemporary regimens presented by Dathan Byonanebye on behalf of the RESPOND Study Group. PRESENTATION
   

Poster presentation:

• Longitudinal CD4:CD8 ratio and CD8 counts and risk of AIDS and non-AIDS defining malignancies in antiretroviral treated people with HIV: The RESPOND cohort consortium presented by Frédérique Chammartin on behalf of the RESPOND Study Group. POSTER
   

Asia-Pacific AIDS & Co-Infections Conference (APACC), Singapore 8-10 June 2023

Poster presentation:

• Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes presented by Dhanushi Rupasignhe on behalf of the RESPOND Study Group. POSTER

12th IAS Conference on HIV Science, Brisbane, Australia, 23-26 July 2023

Oral presentations:

• Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes presented by Dhanushi Rupasignhe on behalf of the RESPOND Study Group. PRESENTATION

• Impact of INSTI and TAF-related DMI changes and risk on hypertension and dyslipidemia in RESPOND presented by Dathan Byonanebye on behalf of the RESPOND Study Group. PRESENTATION

19th European AIDS Conference (EACS), Warsaw, Poland. 18-21 October 2023

Oral presentation:

• Modifiable risk factors and their population attributable fractions for TB in People with HIV across Europe will be presented by Christian Kraef on behalf of the RESPOND Study Group.